Reuters logo
BRIEF-Genmab receives positive opinion from EMA commitee on Arzerra
May 23, 2014 / 1:10 PM / 3 years ago

BRIEF-Genmab receives positive opinion from EMA commitee on Arzerra

COPENHAGEN, May 23 (Reuters) - Danish biotech company Genmab A/S said on Friday: * GSK and Genmab has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Arzerra in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) who are not eligible for fludarabine-based therapy. * Final decision from European commission expected in the coming months Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below